TheraPten Biosciences is Biotechnology in Canada that focus on clinical biotechnological research business. Founded in 2016. They cover business area such as Provider, pre-clinical biotechnological research and development service, naturally-occur anti-cancer therapeutic protein, potent tumor suppressor protein, many human cancer, health worker, cancer-relate disease.
2016
( 8 years old in 2024 )
Clinical Biotechnological Research
-
101-1865 Dilworth Drive
Suite 705
Kelowna, British Columbia V1Y 9T1
Canada
Private
Providerpre-clinical biotechnological research and development servicenaturally-occur anti-cancer therapeutic proteinpotent tumor suppressor proteinmany human cancerhealth workercancer-relate disease
* We use standard office opening hours in near TheraPten Biosciences's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
TheraPten Biosciences is Biotechnology business from Canada that founded in 2016 (8 years old in 2024), TheraPten Biosciences business is focusing on Clinical Biotechnological Research.
TheraPten Biosciences headquarter office and corporate office address is located in 101-1865 Dilworth Drive Suite 705 Kelowna, British Columbia V1Y 9T1 Canada.
TheraPten Biosciences was founded in Canada.
In 2024, TheraPten Biosciences is currently focus on clinical biotechnological research sector.
Above is snippet of Google Trends for "clinical biotechnological research" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with TheraPten Biosciences, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
